1. ‘Orphan business models: toward a new form of intellectual property’;Abramowicz;Harv Law Rev,2011
2. ‘Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?’;Alqahtani;Pharmacoepidemiol Drug Saf,2015
3. ‘Rare diseases, drug development, and AIDS: the impact of the orphan drug act’;Arno;Milbank Q,1995
4. ‘Personalized medicine and rescuing “unsafe” drugs with pharmacogenomics: a regulatory perspective’;Avery;Food Drug Law J,2010
5. Aymé, S., and Hivert, V. (2011). Report on rare disease research, its determinants in Europe and the way forward: iNSERM.